Gowthami M Arepally1, Marcie J Hursting. 1. Division of Hematology, Duke University Medical Center, DUMC Box 3486, Room 304 Sands Building, Research Drive, Durham, NC 27710, USA. arepa001@mc.duke.edu
Abstract
PURPOSE: We determined the seroprevalence of platelet factor 4 (PF4)/heparin antibodies in healthy subjects. METHODS: A literature search identified studies in which healthy subjects were evaluated using commercial immunoassays for PF4/heparin antibody (IgG/M/A). Proportions of test-positive subjects were calculated, by assay. RESULTS: Across 11 eligible studies, 860 healthy subjects were tested using the Stago enzyme-linked immunosorbent assay (ELISA) (nine studies), GTI ELISA (three studies), and/or DiaMed particle gel immunoassay (PGIA) (three studies). Seropositivity occurred in 17 of 790 (2.2%, 95% CI, 1.1-3.2%) subjects by Stago ELISA, one of 100 (1.0%, 95% CI, 0-3.0%) subjects by GTI ELISA, and three of 70 (4.3%, 95% CI, 0-9.0%) subjects by PGIA (P > 0.20). Of seven seropositive subjects tested further, none had platelet-activating antibodies. CONCLUSION: Commercial immunoassays detect PF4/heparin antibody in 1.0-4.3% of healthy subjects. Because this "background" prevalence overlaps seropositivity rates in heparin-treated patients in various clinical settings, normality cut-offs may require refinement.
PURPOSE: We determined the seroprevalence of platelet factor 4 (PF4)/heparin antibodies in healthy subjects. METHODS: A literature search identified studies in which healthy subjects were evaluated using commercial immunoassays for PF4/heparin antibody (IgG/M/A). Proportions of test-positive subjects were calculated, by assay. RESULTS: Across 11 eligible studies, 860 healthy subjects were tested using the Stago enzyme-linked immunosorbent assay (ELISA) (nine studies), GTI ELISA (three studies), and/or DiaMed particle gel immunoassay (PGIA) (three studies). Seropositivity occurred in 17 of 790 (2.2%, 95% CI, 1.1-3.2%) subjects by Stago ELISA, one of 100 (1.0%, 95% CI, 0-3.0%) subjects by GTI ELISA, and three of 70 (4.3%, 95% CI, 0-9.0%) subjects by PGIA (P > 0.20). Of seven seropositive subjects tested further, none had platelet-activating antibodies. CONCLUSION: Commercial immunoassays detect PF4/heparin antibody in 1.0-4.3% of healthy subjects. Because this "background" prevalence overlaps seropositivity rates in heparin-treated patients in various clinical settings, normality cut-offs may require refinement.
Authors: Brian Untch; Sarfraz Ahmad; Walter P Jeske; Harry L Messmore; Debra A Hoppensteadt; Jeanine M Walenga; Helen Lietz; Jawed Fareed Journal: Thromb Res Date: 2002-01-15 Impact factor: 3.944
Authors: J Amiral; F Bridey; M Wolf; C Boyer-Neumann; E Fressinaud; A M Vissac; E Peynaud-Debayle; M Dreyfus; D Meyer Journal: Thromb Haemost Date: 1995-01 Impact factor: 5.249
Authors: Taylor S Cohen; Elizabeth J Kelly; Sven Nylander; Himanshu Bansal; Brett M Jepson; Prakash Bhuyan; Magdalena E Sobieszczyk; Ann R Falsey Journal: Sci Rep Date: 2022-05-13 Impact factor: 4.996
Authors: Robert L Levine; Georgene W Hergenroeder; John L Francis; Charles C Miller; Marcie J Hursting Journal: J Thromb Thrombolysis Date: 2010-08 Impact factor: 2.300
Authors: Joseph J Naoum; Nibal R Chamoun; Mitul S Patel; Tiffany K Street; Mazen Haydar; Jean Bismuth; Hosam F El-Sayed; Mark G Davies; Alan B Lumsden; Eric K Peden Journal: Thrombosis Date: 2014-02-06